Source - RNS
RNS Number : 5908I
Bank of Nova Scotia
31 August 2016
 

The Bank of Nova Scotia and Scotiabank Europe plc

August 31, 2016

 

Publication of Prospectus Supplement

 

The First Supplement (as defined below) to the Prospectus dated June 28, 2016 (the "Prospectus") has been approved by the UK Listing Authority and is available for viewing:

 

First Supplement dated August 31, 2016 to the Prospectus dated June 28, 2016 relating to the U.S.$20,000,000,000 Euro Medium Term Note Programme of The Bank of Nova Scotia and Scotiabank Europe plc

 

The First Supplement (the "First Supplement"), has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM.

 

To view the First Supplement, including the document incorporated by reference therein, please click on the links below or, alternatively, paste the following URLs into the address bar of your Internet browser:

 

First Supplement dated August 31, 2016 relating to the U.S.$20,000,000,000 Euro Medium Term Note Programme of The Bank of Nova Scotia and Scotiabank Europe plc


http://www.rns-pdf.londonstockexchange.com/rns/5908I_-2016-8-31.pdf

 

Document incorporated by reference in the Prospectus:

 

The Bank of Nova Scotia's comparative unaudited interim consolidated financial statements for the three and nine month periods ended July 31, 2016, prepared in accordance with International Financial Reporting Standards, together with management's discussion and analysis for the three and nine month periods ended July 31, 2016, set out on pages 3 through 63 of The Bank of Nova Scotia's 2016 Third Quarter Report to Shareholders

 

http://www.rns-pdf.londonstockexchange.com/rns/5908I_1-2016-8-31.pdf 

 

For further information, please contact:

 

The Bank of Nova Scotia

Scotia Plaza

40 King Street West

Toronto, Ontario

Canada M5H 1H1

 

Attn: Managing Director, Secured & Capital Funding

Tel.: 001 416 933 7974

Fax: 001 416 945 4588

 

DISCLAIMER - INTENDED ADDRESSEES

 

Please note that the information contained in the Prospectus as supplemented by the First Supplement may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus as supplemented by the First Supplement) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Prospectus as supplemented by the First Supplement is not addressed. Prior to relying on the information contained in the Prospectus as supplemented by the First Supplement you must ascertain from the Prospectus as supplemented by the First Supplement whether or not you are part of the intended addressees of the information contained therein.

 

The Notes to be offered under the Programme and the Prospectus as supplemented by the First Supplement have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and are subject to US tax law requirements. Subject to certain exceptions, these Notes may not be offered, sold or delivered in the United States or to or for the account of US persons (as defined in Regulation S under the Securities Act).

 

Your right to access the Prospectus as supplemented by the First Supplement and this service is conditional upon complying with the above requirements.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PDIXFLFXQVFEBBE